What does this research mean for the field?

In real-world practice, ribociclib plus endocrine therapy provides a median progression-free survival of 31.0 months with manageable toxicity in patients with HR-positive/HER2-negative metastatic breast cancer, with higher Ki-67 levels predicting poorer outcomes. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate real-world efficacy, safety, and prognostic determinants of progression-free survival in patients with HR-positive/HER2-negative metastatic breast cancer receiving ribociclib.

September 15, 2026Expert Review of Anticancer Therapy

Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors

View Full Paper

Ask AI

Bookmark

Authors

SKSalih KaratlıMemorial Ankara Hospital DYDoğan YazılıtaşMemorial Ankara Hospital MAMustafa AltınbaşMemorial Ankara Hospital

Discussion

Member takes

Implication

Retrospective study demonstrates favorable progression-free survival with ribociclib in HR-positive metastatic breast cancer, indicating manageable real-world toxicity.

Key Points

To evaluate real-world efficacy, safety, and prognostic determinants of progression-free survival in patients with HR-positive/HER2-negative metastatic breast cancer receiving ribociclib.
Retrospective single-center study evaluating 110 patients treated with ribociclib plus endocrine therapy between January 2023 and January 2026.
Progression-free survival was analyzed via Kaplan–Meier estimation, Cox proportional hazards regression, and a 3-month landmark analysis to evaluate the impact of early dose reductions and grade 3–4 neutropenia.
Median follow-up was 35.0 months (95% CI: 30.2–39.8), yielding an overall median progression-free survival of 31.0 months (95% CI: 24.5–37.5) with no significant difference between first-line and later-line settings (p = 0.148).
Grade 3–4 neutropenia occurred in 36.4% of patients and 36.4% required dose modification, but landmark analysis showed neither early event significantly affected subsequent progression-free survival.
Multivariable analysis identified Ki-67 as a prognostic factor, with each 10-percentage-point increase associated with reduced progression-free survival (HR = 1.203; 95% CI: 1.007–1.436; p = 0.041).

Cite This Study

Karatlı et al. (2026) studied this question.

synapsesocial.com/papers/6aa913a29013453be30a1bc8 https://doi.org/10.1080/14737140.2026.2733826

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study demonstrates favorable progression-free survival with ribociclib in HR-positive metastatic breast cancer, indicating manageable real-world toxicity.

Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider